Status:
ENROLLING_BY_INVITATION
Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease
Lead Sponsor:
Verve Therapeutics, Inc.
Conditions:
Atherosclerotic Cardiovascular Disease
Heterozygous Familial Hypercholesterolemia
Eligibility:
All Genders
18+ years
Brief Summary
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. P...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- A participant has completed or discontinued from a Verve sponsored clinical study in which they received at least one dose of study drug.
- A participant has provided informed consent for LTF-001.
- Exclusion Criteria: N/A
Exclusion
Key Trial Info
Start Date :
June 9 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2039
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT06112327
Start Date
June 9 2024
End Date
October 1 2039
Last Update
November 27 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Study Center
Auckland, New Zealand
2
Clinical Study Center
Christchurch, New Zealand
3
Clinical Study Center
London, United Kingdom